[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","jfky6wvny95s42qnh3ie11y34","revision",2,"title","Valion Bio 完成 LarmorBio BioScan-NMR™ 平台初步可行性评估","originalTitle","8-K - Valion Bio, Inc. (0001787740) (Filer)","summary","Valion Bio 完成 LarmorBio BioScan-NMR™ 平台初步可行性评估。该平台用于生物分子分析，评估结果已通过 press release 公布。公司未披露具体评估细节或后续计划。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-15T12:00:14.000Z","discoveredAt","2026-10-15T12:04:52.396Z","timelineAt","category","tip","tags",[81],"stockSymbols",[80],"score",21,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fHuihv8ESt8Y",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c4528120-4a51-41ab-a08c-00fad176a035","Valion Bio 完成 BioScan-NMR 平台评估",{"_72":73,"_15":74},"zh","

UNITED STATES
\nSECURITIES AND EXCHANGE COMMISSION
\nWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934

Date of Report (Date\nof earliest event reported): October 15, 2026

Valion\nBio, Inc.

(Exact name of Registrant as Specified in Its\nCharter)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Delaware	001-41052	81-4016391
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1305 E. Houston Street, \n Building 1, Suite 311
San Antonio, Texas		78205
(Address of Principal Executive Offices)		(Zip Code)

\n \n \n

Registrant’s Telephone Number, Including Area Code: 888 276-6888

Check the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)\nof the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title of each class		Trading Symbol(s)		\nName of each exchange on which registered
Common Stock, par value $0.0001 per share		VBIO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐

Item 8.01.\nOther Matters.

On October 15,\n2026, Valion Bio, Inc. (the “Company”) issued a press release announcing completion of an initial feasibility evaluation of\nLarmorBio's BioScan-NMR™ platform.

A copy of the\npress release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein\nby reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit

Number

Description

99.1

Press Release, dated October 15, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

Forward-Looking Statements

This Current Report, including Exhibit 99.1 attached hereto, contains certain\nforward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,”\n“estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are\nintended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibit 99.1\nattached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the\n“SEC”), reports to the stockholders of the Company and other publicly available statements issued or released by us involve\nknown and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or\nachievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking\nstatements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results\nof operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the SEC,\neach of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results,\nperformance or achievements may differ materially and adversely from those expressed or implied by such forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

			VALION BIO, INC.

Date:	October 15, 2026	By:	/s/ Dean Zikria
			Name: Dean Zikria \nTitle: Interim Chief Executive Officer

","zhKind","complete","VBIO","政策与监管","aihot","/items/jfky6wvny95s42qnh3ie11y34","https://www.sec.gov/Archives/edgar/data/1787740/000168316826007857/0001683168-26-007857-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]